Tempus AI is a healthcare technology company that uses artificial intelligence to analyse clinical and molecular data — helping physicians make more personalised treatment decisions. The company went public in 2024 and its stock (TEM on NASDAQ) attracted significant interest from investors tracking AI-focused public companies.
What Tempus AI Does
Tempus AI's core business is building a data platform for oncology and other medical specialties. It processes genomic sequencing data, clinical trial data, and patient records to identify patterns that inform treatment choices. Its tools are used primarily by hospitals and cancer centres in the United States. In 2025, it expanded into drug discovery and chronic disease management.
Why Investors Are Tracking It
Tempus AI represents a category of AI companies applying machine learning to large, proprietary datasets in regulated industries — where data network effects create competitive moats. Investors tracking AI sector exposure have identified healthcare AI (alongside AI infrastructure and enterprise AI software) as one of the highest-conviction categories for the 2025–2028 investment period.
AI Investment Context for Qatar
Qatar Investment Authority (QIA) and regional sovereign wealth funds have made significant allocations to AI-adjacent investments — AI infrastructure, data centres, and AI-enabled enterprise software. For individual investors in Qatar interested in AI sector exposure, US-listed AI companies including Tempus, Nvidia, Microsoft, and Alphabet are accessible through international brokerage platforms. This is not investment advice; consult a licensed financial advisor for specific decisions.